Thalidomide R- and S- enantiomer molecules 3D model

cgtrader

This model encompasses two pivotal components: the R-enantiomer and the S-enantiomer of Thalidomide. The R-enantiomer (formula: C13H10N2O4; CAS Number: 2614-06-4) possesses a systematic name of (R)-(+)-thalidomide. In contrast, the S-enantiomer (formula: C13H10N2O4; CAS Number: 841-67-8) is referred to as (S)-(-)-thalidomide. A combination of both R- and S-enantiomers constitutes a racemic mixture with a unique CAS number - 50-35-1. The widespread use of thalidomide during the early days attempted to mitigate morning sickness, yet unborn children subjected to this medication endured devastating repercussions such as phocomelia, ocular abnormalities, heart deformities, and urinary tract irregularities. This led to instances of deafness and blindness in these children. The profound negative consequences resulting from the use of thalidomide triggered the initiation of more rigid drug regulatory policies worldwide. Thalidomide was initially administered with hopes that it could help alleviate morning sickness, yet its use while pregnant ultimately proved disastrous for the babies involved who were subjected to phocomelia among many other issues such as defects to the eyes and urinary tract, a condition that also caused them to lose their vision entirely or struggle with hearing in ways like never before. Due to this extremely hazardous effects of thalidomide there came new strict policies across the globe designed for safer pharmaceutical research development and oversight